16 results
DEF 14A
CRGX
CARGO Therapeutics Inc
24 Apr 24
Definitive proxy
4:27pm
of individual performance and near-term corporate targets as well as long-term business objectives.
Our NEOs for 2023 were as follows:
Gina Chapman
10-K
2023 FY
CRGX
CARGO Therapeutics Inc
21 Mar 24
Annual report
4:21pm
tumor cells with three B-cell antigen targets, CD19, CD20 and CD22. This product candidate also integrates a CD2 co-stimulatory domain into the tri … is an autologous CAR T-cell product candidate that targets CD22, a B-cell specific antigen that has been reported to be expressed in 81% to 100% of diffuse
10-Q
2023 Q3
CRGX
CARGO Therapeutics Inc
13 Dec 23
Quarterly report
4:31pm
certain initial targets, and upon payment of certain fees, additional targets as agreed by Oxford and the Company.
As consideration for the license
S-8
EX-99.2
85j3yszmtyst9l
14 Nov 23
Registration of securities for employees
7:52pm
424B4
k0yx5kn
13 Nov 23
Prospectus supplement with pricing info
4:31pm
S-1/A
EX-10.2
vpl77ube
1 Nov 23
IPO registration (amended)
5:20pm
S-1
6m24ubs1
20 Oct 23
IPO registration
4:07pm
S-1
EX-10.4
7qjc9g5fc2y jp1vksc
20 Oct 23
IPO registration
4:07pm
DRS/A
lke4x57i13oak7mwl3j
4 Oct 23
Draft registration statement (amended)
12:00am
DRS
u8vwzb0nu
1 Sep 23
Draft registration statement
12:00am
- Prev
- 1
- Next